128 related articles for article (PubMed ID: 36640105)
1. Impact of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation.
Hirai T; Morikawa Y; Onishi R; Nakatani Y; Nishikawa K; Inoue T; Iwamoto T
Br J Clin Pharmacol; 2023 Jun; 89(6):1852-1861. PubMed ID: 36640105
[TBL] [Abstract][Full Text] [Related]
2. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
[TBL] [Abstract][Full Text] [Related]
3. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
4. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression.
Pasari AS; Balwani MR; Gurjar P; Bawankule C; Bhawane A; Tolani P; Kashiv P; Dubey S; Katekhaye VM
Transplant Proc; 2023 Jun; 55(5):1305-1309. PubMed ID: 36973144
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
[TBL] [Abstract][Full Text] [Related]
7. Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy.
Pasternak AL; Marcath LA; Li Y; Nguyen V; Gersch CL; Rae JM; Frame D; Scappaticci G; Kidwell KM; Hertz DL
Transplant Cell Ther; 2022 Jan; 28(1):19.e1-19.e7. PubMed ID: 34583027
[TBL] [Abstract][Full Text] [Related]
8. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients.
Largeau B; Guellec CB; Longuet H; Lesne P; Bouvarel A; Préteseille L; Marquet P; Halimi JM; Büchler M; Gatault P; Noble J
Prog Transplant; 2019 Dec; 29(4):300-308. PubMed ID: 31514576
[TBL] [Abstract][Full Text] [Related]
10. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
[TBL] [Abstract][Full Text] [Related]
12. Effects of donor-recipient combinational CYP3A5 genotypes on tacrolimus dosing in Chinese DDLT adult recipients.
Liu J; Chen D; Yao B; Guan G; Liu C; Jin X; Wang X; Liu P; Sun Y; Zang Y
Int Immunopharmacol; 2020 Mar; 80():106188. PubMed ID: 31931373
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
14. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Tacrolimus Intra-Patient Variability during 6-12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers.
Nuchjumroon A; Vadcharavivad S; Singhan W; Poosoonthornsri M; Chancharoenthana W; Udomkarnjananun S; Townamchai N; Avihingsanon Y; Praditpornsilpa K; Eiam-Ong S
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362548
[TBL] [Abstract][Full Text] [Related]
16. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.
Zong YP; Wang ZJ; Zhou WL; Zhou WM; Ma TL; Huang ZK; Zhao CC; Xu Z; Tan RY; Gu M
World J Pediatr; 2017 Oct; 13(5):421-426. PubMed ID: 28540692
[TBL] [Abstract][Full Text] [Related]
18. Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients.
Xing J; Zhang X; Fan J; Shen B; Men T; Wang J
Eur J Clin Pharmacol; 2015 Feb; 71(2):191-8. PubMed ID: 25487141
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interaction between tacrolimus and caspofungin in Chinese kidney transplant patients with different
Zhang Y; Shen B; Li Y; Zong H; Zhang X; Cao X; Liu F; Li Y
Ther Adv Drug Saf; 2024; 15():20420986241243165. PubMed ID: 38646424
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
